NCT05011045 Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
| NCT ID | NCT05011045 |
| Status | Recruiting |
| Phase | — |
| Sponsor | M.D. Anderson Cancer Center |
| Condition | Central Nervous System Lymphoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2020-01-09 |
| Primary Completion | 2026-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2020-01-09 with a primary completion date of 2026-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study assesses neurocognitive outcomes after receiving radiation therapy to the brain (whole brain radiation therapy) in patients with blood cancers (hematologic malignancies). This may help researchers learn more about the effects of whole brain radiation therapy on memory and thinking in patients with blood cancer.
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older * Treatment with radiation therapy to the brain for a hematologic malignancy (ex. primary central nervous system lymphoma \[PCNSL\], secondary central nervous system lymphoma \[SCNSL\], leukemia, myeloma) * Proficient and capable of completing tests in English * Patients with claustrophobia are eligible if the claustrophobia is managed with medication * Patients with cognitively-impairment are eligible if the impairment is managed with medication * Patients who are pregnant
Contact & Investigator
Bouthaina S Dabaja
PRINCIPAL INVESTIGATOR
M.D. Anderson Cancer Center
Frequently Asked Questions
Who can join the NCT05011045 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Central Nervous System Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05011045 currently recruiting?
Yes, NCT05011045 is actively recruiting participants. Contact the research team at dmdmsilk@mdanderson.orgsilk@mdanderson.org for enrollment information.
Where is the NCT05011045 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT05011045 clinical trial?
NCT05011045 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Bouthaina S Dabaja at M.D. Anderson Cancer Center. The trial plans to enroll 100 participants.